Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:36:23.042Z.
Calculation as of: 2026-10-06T15:36:23.042Z.
Quote observation: 2026-10-06T15:34:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4140271b5ba2e17517ffa776ba39ee0784cb590c71b20d0313403f3757235181
PE RATIO
N/A
Market Cap
$1.13B
PE Ratio
15.22
TTM Avg
11.54
3Y Avg
13.50
5Y Avg
19.40
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.17B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.17B | N/A | 10.01 | 10.01 | 83.50 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | N/A | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 78.24 | 42.78 | 72.87 | 84.11 |
| OPKO Health, Inc. (OPK)vs › | $1.14B | N/A | 38.94 | 40.17 | 40.17 |
| Innovage Holding Corp. (INNV)vs › | $1.21B | N/A | 92.39 | 92.39 | 92.39 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 15.22 | 11.54 | 13.50 | 19.40 |
| Harrow Health, Inc. (HROW)vs › | $1.13B | N/A | 47.35 | 23.64 | 23.64 |
| MannKind Corporation (MNKD)vs › | $1.22B | N/A | 65.92 | 100.90 | 100.90 |
| Omada Health (OMDA)vs › | $1.22B | 325.95 | 351.15 | 351.15 | 351.15 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$19.07
Forward EPS (Est.)
$-2.04
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
